Cerus Corporation (CERS)

Market Cap	340.14M +11.7%
Revenue (ttm)	206.13M +14.3%
Net Income	-15.63M
EPS	-0.08
Shares Out	192.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,400,653
Open	1.900
Previous Close	1.930
Day's Range	1.770 - 1.913
52-Week Range	1.120 - 2.955
Beta	1.53
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 2, 2026

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 1997
• Employees: 630
• Stock Exchange: NASDAQ
• Ticker Symbol: CERS
• Website: https://www.cerus.com

Financial Performance

In 2025, Cerus's revenue was $206.13 million, an increase of 14.35% compared to the previous year's $180.27 million. Losses were -$15.63 million, -25.29% less than in 2024.